Neogen Chemicals Limited manufactures specialty chemicals including bromine-based compounds, lithium compounds and advanced intermediates used in pharmaceuticals, electronics and other industries. Its specialized product portfolio provides exposure to high-value chemical applications. Growth in electronics, pharmaceuticals, energy-storage and specialty chemical markets can support expansion. Raw-material costs, chemical cycles, regulatory requirements, capacity utilization and competition remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹6,795 cr | ₹926 cr | ₹36 cr | 186.7 | 13.29 | 8.32 | 3.6% | 4.5% | 6.6% | 1.63 | ₹-787 cr | 56.6 | 0.84 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 250 | 17 | 6.29 | +61.7% | +34.0% | 6.8% |
| Mar 2026 | 247 | 11 | 4.32 | +374.7% | +21.6% | 4.6% |
| Dec 2025 | 220 | 4 | 1.40 | -63.2% | +9.2% | 1.7% |
| Sep 2025 | 209 | 3 | 1.28 | -69.2% | +7.9% | 1.6% |
| Jun 2025 | 187 | 10 | 3.89 | -10.6% | +3.8% | 5.5% |
| Mar 2025 | 203 | 2 | 0.91 | -85.8% | +1.6% | 1.2% |
| Dec 2024 | 201 | 10 | 3.80 | +826.8% | +22.5% | 5.0% |
| Sep 2024 | 193 | 11 | 4.15 | +30.9% | +19.6% | 5.7% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✓ Pass |
| EPS growth accelerating over 3 quarters | ✗ Fail |
| Sales up 25%+, or sales growth accelerating | ✓ Pass |
| Annual EPS up 25%+ in each of the last 2 years | ✗ Fail |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 979.80 ✓ Within 25% of the 52-week high · high 2,687.90 ✓ RS percentile 70 or more · RS 90 Trend template - the gate, measured: a modest 21-day edge. | 8/8 | Pass |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✓ C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 2,687.90 ✓ S more volume on up days than down days (50 sessions) · 2.00x ✓ L RS percentile 80 or more · RS 90 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 5/6 | Strong |
| Darvas | ✗ Box top confirmed (3 sessions below the new high) · top 2,785.00 — Box bottom confirmed (3 sessions holding) ✗ Close above the box top · close 2,481.80 ✗ Volume at least 1.5x its 50-day average · 0.5x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 56/100 | Forming |
| Turtle | ✗ Close above the prior 55-session high · 2,785.00 ✗ Close above the prior 20-session high · 2,785.00 ✗ Close below the prior 20-session low · 2,296.70 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 1.8% — Return on capital (ROCE) · 6.6% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 6/100 | Weak |
| Graham | ✗ Price at or below the Graham number · Graham number 298.66 ✗ P/E 15 or less · P/E 186.7 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 8.32 ✗ Current ratio 2 or more · 1.17 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 12/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✗ Operating cash flow positive ✗ ROA rising ✗ Cash flow above net profit (earnings quality) ✗ Long-term debt / assets falling ✗ Current ratio rising · 1.17 ✓ No new shares issued ✗ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 2/9 | Weak |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NEOGEN this stock | -0.3 | +13.7 | +66.1 | +70.0 | +43.2 | +81.2 | 186.7 | 8.32 | 3.6 | 6.6 | — | 1.63 | 56.6 | 6,795 | 926 | 36 | 13.3 | 0.84 |
| BODALCHEM | -14.3 | +149.1 | +142.6 | +175.9 | +104.7 | +20.3 | 30.1 | 1.78 | 4.2 | 6.7 | — | 0.69 | 14.2 | 2,065 | 2,267 | 69 | 5.5 | 0.70 |
| RPEL | +7.6 | +38.6 | +149.7 | +161.5 | — | — | 115.8 | 28.99 | 25.0 | 31.2 | — | 0.02 | 85.7 | 8,164 | 315 | 70 | 15.3 | 1.42 |
| FCL | -2.1 | +41.7 | +142.9 | +128.2 | +70.0 | +356.5 | 43.9 | 7.36 | 13.5 | 18.3 | — | 0.01 | 39.5 | 6,499 | 1,012 | 148 | 1.3 | 1.46 |
| AETHER | -6.7 | +4.9 | +28.3 | +104.1 | +70.3 | — | 85.6 | 8.22 | 9.4 | 11.6 | — | 0.18 | 55.5 | 20,191 | 1,224 | 235 | 17.8 | 0.75 |
| KRISHANA | +18.3 | +46.5 | +66.7 | +87.6 | +322.8 | +1076.5 | 33.5 | 11.74 | 38.1 | 27.3 | — | 1.31 | 22.8 | 6,581 | 2,555 | 197 | 6.4 | 1.04 |
| OAL | +21.4 | +78.0 | +98.3 | +85.2 | +69.9 | -28.9 | 395.2 | 3.16 | 0.5 | 4.5 | — | 0.61 | 32.3 | 2,101 | 1,065 | 5 | 1.6 | 0.97 |
| NAVINFLUOR | -5.1 | +3.7 | +26.0 | +59.6 | +123.5 | +111.1 | 52.9 | 10.52 | 20.1 | 21.4 | — | 0.31 | 37.8 | 41,822 | 3,634 | 790 | 154.2 | 0.78 |
| VALIANTORG | +9.1 | +74.3 | +72.0 | +59.4 | -0.5 | -70.1 | 24.0 | 1.72 | 4.5 | 6.2 | — | 0.33 | 15.5 | 1,305 | 766 | 54 | 19.4 | 1.02 |
| ICIL | -5.3 | +8.0 | +58.0 | +58.8 | +74.0 | +46.7 | 55.6 | 3.56 | 5.5 | 8.7 | — | 0.46 | 21.0 | 8,394 | 4,390 | 151 | 7.6 | 1.50 |
| JGCHEM | +0.2 | +25.5 | +60.0 | +50.2 | — | — | 32.0 | 4.55 | 13.3 | 18.1 | — | 0.01 | 25.4 | 2,405 | 1,071 | 78 | 19.2 | 1.37 |